ReviewExpert review of molecular diagnostics2012
How many molecular subtypes? Implications of the unique tumor principle in personalized medicine.
Review in Expert review of molecular diagnostics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed.
- Evaluating the utility ofEpigenetics · 2024Trial
- Assessing Similarity Among Individual Tumor Size Lesion Dynamics: The CICIL Methodology.CPT: pharmacometrics & systems pharmacology · 2018Trial
- Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.Journal of the National Cancer Institute · 2013Trial
- Novel nested conformal prediction analysis to unravel complexity in patient subtyping.Frontiers in artificial intelligence · 2026Article
- TRP channels and cancer modulation: a voyage beyond metabolic reprogramming, oxidative stress and the advent of nanotechnologies in targeted therapy.Journal of experimental & clinical cancer research : CR · 2025Review
- Gene signatures for cancer research: A 25-year retrospective and future avenues.PLoS computational biology · 2024Article
- All-In-One OsciDrop Digital PCR System for Automated and Highly Multiplexed Molecular Diagnostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Prolonged HPA axis dysregulation in postpartum depression associated with adverse early life experiences: A cross-species translational study.Nature. Mental health · 2024Article
- Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy.British journal of cancer · 2024Review
- ICOS/ICOSLG and PD-1 Co-Expression is Associated with the Progression of Colorectal Precancerous- Carcinoma Immune Microenvironment.Journal of inflammation research · 2023Article
- Improve consensus partitioning via a hierarchical procedure.Briefings in bioinformatics · 2022Article
- Computational Approaches Integrated in a Digital Ecosystem Platform for a Rare Disease.Frontiers in molecular medicine · 2022Review
- Chemotherapy induces feedback up-regulation of CD44v6 in colorectal cancer initiating cells throughFrontiers in oncology · 2022Article
- A survey on multi-omics-based cancer diagnosis using machine learning with the potential application in gastrointestinal cancer.Frontiers in medicine · 2022Review
- Article
- Recapitulating the Cancer Microenvironment Using Bioprinting Technology for Precision Medicine.Micromachines · 2021Review
- Transcriptome of CD8Cancer immunology, immunotherapy : CII · 2021Article
- Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment.Molecules (Basel, Switzerland) · 2021Review
- Artificial intelligence in cancer research: learning at different levels of data granularity.Molecular oncology · 2021Review
- Patient-derived scaffolds as a model of colorectal cancer.Cancer medicine · 2021Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cancers are complex multifactorial diseases. For centuries, conventional organ-based classification system (i.e., breast cancer, lung cancer, colon cancer, colorectal cancer, prostate cancer, lymphoma, leukemia, and so on) has been utilized. Recently, molecular diagnostics has become an essential component in clinical decision-making. However, tumor evolution and behavior cannot accurately be predicted, despite numerous research studies reporting promising tumor biomarkers. To advance molecular diagnostics, a better understanding of intratumor and intertumor heterogeneity is essential. Tumor cells interact with the extracellular matrix and host non-neoplastic cells in the tumor microenvironment, which is influenced by genomic variation, hormones, and dietary, lifestyle and environmental exposures, implicated by molecular pathological epidemiology. Essentially, each tumor possesses its own unique characteristics in terms of molecular make-up, tumor microenvironment and interactomes within and between neoplastic and host cells. Starting from the unique tumor concept and paradigm, we can better classify tumors by molecular methods, and move closer toward personalized cancer medicine and prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.